Kangliflozin hemihydrate is a kind of hydrate of kangliflozin. The chemical name of canagliflozin is 1-( β- D-glucopyranosyl) - 4-methyl-3 - [5 - (4-fluorophenyl) - 2-thienylmethyl] benzene was developed by Johnson & Johnson's subsidiary, Janssen Pharmaceutical Company. Canglitazin is a chemical Book selective sodium glucose transporter type 2 (sglt-2) inhibitor, which can specifically inhibit the reabsorption of glucose by the kidney, so that excess glucose can be excreted from the urine, thus directly reducing the blood glucose level. The drug was approved by FDA in March 29, 2013 for the treatment of type II diabetes, the trade name is Invokana.